tiprankstipranks
Trending News
More News >
Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
US Market

Virax Biolabs Group Ltd. Class A (VRAX) Stock Forecast & Price Target

Compare
104 Followers
See the Price Targets and Ratings of:

VRAX Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Virax
Biolabs Group Ltd. Class A
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRAX Stock 12 Month Forecast

Average Price Target

$3.00
▲(194.12% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Virax Biolabs Group Ltd. Class A in the last 3 months. The average price target is $3.00 with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 194.12% change from the last price of $1.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,1.7723076923076921,1.8746153846153846,1.9769230769230768,2.079230769230769,2.1815384615384614,2.2838461538461536,2.386153846153846,2.4884615384615385,2.5907692307692307,2.693076923076923,2.7953846153846156,2.8976923076923073,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,1.7723076923076921,1.8746153846153846,1.9769230769230768,2.079230769230769,2.1815384615384614,2.2838461538461536,2.386153846153846,2.4884615384615385,2.5907692307692307,2.693076923076923,2.7953846153846156,2.8976923076923073,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,1.7723076923076921,1.8746153846153846,1.9769230769230768,2.079230769230769,2.1815384615384614,2.2838461538461536,2.386153846153846,2.4884615384615385,2.5907692307692307,2.693076923076923,2.7953846153846156,2.8976923076923073,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.74,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.65,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.18,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.1,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.13,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.66,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.62,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.04,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.95,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.69,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.67,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3.00Average Price Target$3.00Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Virax Biolabs Group Ltd. Class A

Which Analyst Should I Follow If I Want to Buy VRAX and Sell After:
1 Month
xxx
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.80%
initiated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -12.80% per trade.
3 Months
xxx
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.80%
initiated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -12.80% per trade.
1 Year
Yi ChenH.C. Wainwright
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.80%
initiated a buy rating 25 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -12.80% per trade.
2 Years
xxx
Success Rate
0/1 ratings generated profit
0%
Average Return
-12.80%
initiated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -12.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRAX Analyst Recommendation Trends

Rating
Mar 25
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
total
1
In the current month, VRAX has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VRAX average Analyst price target in the past 3 months is 3.00.
Each month's total comprises the sum of three months' worth of ratings.

VRAX Financial Forecast

VRAX Earnings Forecast

The previous quarter’s earnings for VRAX were -$1.24.
The previous quarter’s earnings for VRAX were -$1.24.

VRAX Sales Forecast

The previous quarter’s earnings for VRAX were $5.76K.
The previous quarter’s earnings for VRAX were $5.76K.

VRAX Stock Forecast FAQ

What is VRAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Virax Biolabs Group Ltd. Class A’s 12-month average price target is 3.00.
    What is VRAX’s upside potential, based on the analysts’ average price target?
    Virax Biolabs Group Ltd. Class A has 194.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRAX a Buy, Sell or Hold?
          Virax Biolabs Group Ltd. Class A has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Virax Biolabs Group Ltd. Class A’s price target?
            The average price target for Virax Biolabs Group Ltd. Class A is 3.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents 194.12% Increase from the current price of $1.02.
              What do analysts say about Virax Biolabs Group Ltd. Class A?
              Virax Biolabs Group Ltd. Class A’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of VRAX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis